| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, erbB-2 | 15 | 2020 | 133 | 4.710 |
Why?
|
| Mammary Neoplasms, Experimental | 11 | 2020 | 70 | 3.990 |
Why?
|
| Breast Neoplasms | 26 | 2022 | 1502 | 3.710 |
Why?
|
| Metformin | 6 | 2022 | 65 | 2.530 |
Why?
|
| Cell Proliferation | 17 | 2022 | 1198 | 2.490 |
Why?
|
| Antineoplastic Agents | 12 | 2022 | 803 | 2.410 |
Why?
|
| Signal Transduction | 15 | 2020 | 1908 | 1.910 |
Why?
|
| Genistein | 5 | 2016 | 42 | 1.810 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2020 | 807 | 1.730 |
Why?
|
| Receptors, Estrogen | 5 | 2018 | 156 | 1.620 |
Why?
|
| Neoplastic Stem Cells | 3 | 2018 | 78 | 1.580 |
Why?
|
| Cell Line, Tumor | 24 | 2022 | 2231 | 1.370 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2017 | 213 | 1.370 |
Why?
|
| Benzhydryl Compounds | 2 | 2020 | 43 | 1.360 |
Why?
|
| Phenols | 2 | 2020 | 80 | 1.320 |
Why?
|
| Mice, Transgenic | 15 | 2020 | 617 | 1.270 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2018 | 47 | 1.200 |
Why?
|
| Apoptosis | 13 | 2018 | 1398 | 1.190 |
Why?
|
| Brain Ischemia | 3 | 2019 | 184 | 1.170 |
Why?
|
| Triazoles | 2 | 2018 | 86 | 1.160 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 172 | 1.110 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2020 | 162 | 1.090 |
Why?
|
| MAP Kinase Signaling System | 5 | 2020 | 169 | 1.020 |
Why?
|
| Estrogen Receptor alpha | 4 | 2020 | 111 | 0.970 |
Why?
|
| E2F1 Transcription Factor | 3 | 2016 | 17 | 0.960 |
Why?
|
| Sirolimus | 4 | 2019 | 60 | 0.960 |
Why?
|
| Genomic Instability | 2 | 2018 | 38 | 0.960 |
Why?
|
| Ethanol | 2 | 2017 | 192 | 0.950 |
Why?
|
| Receptor, IGF Type 1 | 3 | 2020 | 26 | 0.940 |
Why?
|
| Genes, erbB-2 | 4 | 2013 | 6 | 0.820 |
Why?
|
| Mice | 19 | 2020 | 5913 | 0.790 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2020 | 1 | 0.760 |
Why?
|
| Nuclear Proteins | 3 | 2012 | 307 | 0.750 |
Why?
|
| Female | 31 | 2022 | 20969 | 0.750 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2020 | 20 | 0.740 |
Why?
|
| Mammary Neoplasms, Animal | 3 | 2017 | 30 | 0.730 |
Why?
|
| Piperazines | 2 | 2017 | 111 | 0.710 |
Why?
|
| Endocrine Disruptors | 1 | 2020 | 39 | 0.700 |
Why?
|
| Caspase 3 | 3 | 2017 | 207 | 0.690 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 194 | 0.680 |
Why?
|
| Seizures | 1 | 2019 | 68 | 0.680 |
Why?
|
| Benzamides | 2 | 2017 | 78 | 0.670 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 24 | 0.670 |
Why?
|
| Hyperglycemia | 1 | 2019 | 55 | 0.660 |
Why?
|
| Up-Regulation | 4 | 2017 | 513 | 0.650 |
Why?
|
| Animals | 23 | 2020 | 15081 | 0.640 |
Why?
|
| Caloric Restriction | 1 | 2018 | 32 | 0.640 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2018 | 29 | 0.640 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 26 | 0.630 |
Why?
|
| Receptor, erbB-3 | 7 | 2017 | 12 | 0.610 |
Why?
|
| Epithelial Cells | 2 | 2018 | 384 | 0.600 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 539 | 0.600 |
Why?
|
| Humans | 36 | 2022 | 37093 | 0.600 |
Why?
|
| Anticarcinogenic Agents | 2 | 2016 | 65 | 0.590 |
Why?
|
| Buformin | 1 | 2017 | 1 | 0.590 |
Why?
|
| Pyrazoles | 1 | 2017 | 85 | 0.580 |
Why?
|
| Quinazolines | 1 | 2017 | 33 | 0.570 |
Why?
|
| Precancerous Conditions | 1 | 2017 | 82 | 0.570 |
Why?
|
| Alcohols | 1 | 2016 | 12 | 0.570 |
Why?
|
| Mammary Glands, Animal | 2 | 2015 | 26 | 0.560 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 95 | 0.550 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2016 | 77 | 0.550 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2020 | 222 | 0.540 |
Why?
|
| Autoantigens | 1 | 2016 | 81 | 0.540 |
Why?
|
| Prosencephalon | 1 | 2015 | 25 | 0.540 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 195 | 0.510 |
Why?
|
| Cell Survival | 6 | 2018 | 864 | 0.500 |
Why?
|
| Stilbenes | 2 | 2015 | 44 | 0.500 |
Why?
|
| Cell Differentiation | 1 | 2018 | 587 | 0.490 |
Why?
|
| DNA Damage | 1 | 2017 | 352 | 0.490 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2016 | 187 | 0.470 |
Why?
|
| Tamoxifen | 5 | 2015 | 65 | 0.470 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 461 | 0.460 |
Why?
|
| Down-Regulation | 5 | 2022 | 435 | 0.450 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2011 | 190 | 0.430 |
Why?
|
| Mammary Tumor Virus, Mouse | 4 | 2020 | 5 | 0.430 |
Why?
|
| Membrane Proteins | 1 | 2016 | 517 | 0.420 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 519 | 0.420 |
Why?
|
| Phosphorylation | 6 | 2019 | 928 | 0.420 |
Why?
|
| Blotting, Western | 8 | 2018 | 859 | 0.390 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 147 | 0.360 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 110 | 0.350 |
Why?
|
| Doxorubicin | 2 | 2007 | 84 | 0.350 |
Why?
|
| Cell Communication | 1 | 2009 | 97 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2017 | 259 | 0.330 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2017 | 55 | 0.330 |
Why?
|
| RNA, Small Interfering | 5 | 2017 | 409 | 0.330 |
Why?
|
| Chromosome Aberrations | 1 | 2008 | 60 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2017 | 269 | 0.310 |
Why?
|
| Caspases | 1 | 2007 | 147 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 152 | 0.280 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 44 | 0.280 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 168 | 0.270 |
Why?
|
| Estradiol | 2 | 2009 | 262 | 0.270 |
Why?
|
| Tumor Cells, Cultured | 4 | 2018 | 502 | 0.250 |
Why?
|
| Cell Cycle | 3 | 2017 | 326 | 0.250 |
Why?
|
| Cytosol | 2 | 2019 | 93 | 0.240 |
Why?
|
| Flow Cytometry | 4 | 2018 | 399 | 0.240 |
Why?
|
| Cocarcinogenesis | 1 | 2003 | 7 | 0.230 |
Why?
|
| Caspase 9 | 2 | 2017 | 30 | 0.220 |
Why?
|
| Isoflavones | 2 | 2005 | 129 | 0.220 |
Why?
|
| Rats | 5 | 2019 | 3483 | 0.220 |
Why?
|
| Caspase 8 | 2 | 2017 | 32 | 0.220 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2017 | 77 | 0.220 |
Why?
|
| Pregnancy | 2 | 2020 | 1549 | 0.210 |
Why?
|
| Cytochromes c | 2 | 2015 | 53 | 0.210 |
Why?
|
| Drug Synergism | 3 | 2018 | 177 | 0.200 |
Why?
|
| Rats, Wistar | 2 | 2019 | 233 | 0.200 |
Why?
|
| Gene Expression | 2 | 2017 | 674 | 0.200 |
Why?
|
| Pyrogallol | 1 | 2020 | 1 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 3 | 2013 | 290 | 0.190 |
Why?
|
| Estrogen Antagonists | 2 | 2015 | 28 | 0.190 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2017 | 132 | 0.180 |
Why?
|
| Sexual Maturation | 1 | 2020 | 23 | 0.180 |
Why?
|
| Cerebral Cortex | 2 | 2019 | 290 | 0.180 |
Why?
|
| Maternal Exposure | 1 | 2020 | 33 | 0.180 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2016 | 133 | 0.180 |
Why?
|
| Sulfonamides | 1 | 2020 | 80 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 623 | 0.180 |
Why?
|
| Anticonvulsants | 1 | 2019 | 34 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1371 | 0.170 |
Why?
|
| Gestational Age | 1 | 2020 | 190 | 0.170 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 893 | 0.170 |
Why?
|
| Cell Death | 1 | 2019 | 267 | 0.160 |
Why?
|
| Half-Life | 1 | 2018 | 54 | 0.160 |
Why?
|
| Mammary Glands, Human | 1 | 2018 | 39 | 0.160 |
Why?
|
| RNA Interference | 2 | 2017 | 243 | 0.150 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2017 | 11 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2015 | 182 | 0.150 |
Why?
|
| Carcinogens | 1 | 2018 | 124 | 0.150 |
Why?
|
| Diet | 2 | 2004 | 801 | 0.150 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1207 | 0.150 |
Why?
|
| Caspase 10 | 2 | 2007 | 2 | 0.150 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 78 | 0.150 |
Why?
|
| Deoxyguanosine | 1 | 2017 | 35 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 40 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 143 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 3 | 2013 | 21 | 0.140 |
Why?
|
| Imidazoles | 1 | 2017 | 126 | 0.140 |
Why?
|
| Stem Cells | 1 | 2017 | 141 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 160 | 0.140 |
Why?
|
| Hippocampus | 1 | 2019 | 561 | 0.130 |
Why?
|
| Salicylates | 1 | 2015 | 9 | 0.130 |
Why?
|
| Histones | 1 | 2017 | 190 | 0.130 |
Why?
|
| DNA Repair | 1 | 2017 | 188 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 251 | 0.130 |
Why?
|
| Cell Transformation, Viral | 1 | 2015 | 29 | 0.130 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2016 | 94 | 0.130 |
Why?
|
| Fetus | 1 | 2015 | 105 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2007 | 356 | 0.120 |
Why?
|
| Models, Biological | 1 | 2018 | 677 | 0.120 |
Why?
|
| Phytoestrogens | 2 | 2005 | 38 | 0.120 |
Why?
|
| Integrin alpha6 | 1 | 2013 | 4 | 0.120 |
Why?
|
| Integrin beta3 | 1 | 2013 | 6 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1039 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 515 | 0.120 |
Why?
|
| Organ Specificity | 1 | 2013 | 129 | 0.110 |
Why?
|
| Cell Movement | 1 | 2016 | 571 | 0.110 |
Why?
|
| Karyotyping | 2 | 2011 | 47 | 0.110 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 76 | 0.110 |
Why?
|
| Transfection | 2 | 2011 | 523 | 0.100 |
Why?
|
| Neurons | 1 | 2019 | 1175 | 0.100 |
Why?
|
| Oncogene Fusion | 1 | 2011 | 1 | 0.100 |
Why?
|
| Philadelphia Chromosome | 1 | 2011 | 3 | 0.100 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2011 | 25 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 172 | 0.100 |
Why?
|
| Plasmids | 1 | 2012 | 246 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 39 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2015 | 1369 | 0.100 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2008 | 69 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2017 | 938 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2011 | 37 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 1618 | 0.090 |
Why?
|
| Pyridines | 1 | 2011 | 116 | 0.090 |
Why?
|
| S Phase | 1 | 2010 | 37 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2013 | 1518 | 0.090 |
Why?
|
| Cell Count | 1 | 2009 | 135 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 578 | 0.090 |
Why?
|
| Protein Isoforms | 1 | 2009 | 130 | 0.090 |
Why?
|
| Radio Frequency Identification Device | 1 | 2008 | 1 | 0.080 |
Why?
|
| Transducers | 1 | 2008 | 12 | 0.080 |
Why?
|
| Telemetry | 1 | 2008 | 14 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2009 | 56 | 0.080 |
Why?
|
| Body Temperature | 1 | 2008 | 36 | 0.080 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2009 | 77 | 0.080 |
Why?
|
| Neoplasms | 1 | 2018 | 1103 | 0.080 |
Why?
|
| Nanotubes, Carbon | 1 | 2009 | 79 | 0.080 |
Why?
|
| Mutation | 1 | 2012 | 1095 | 0.080 |
Why?
|
| Biosensing Techniques | 1 | 2009 | 86 | 0.080 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2007 | 2 | 0.080 |
Why?
|
| Caspases, Initiator | 1 | 2007 | 4 | 0.070 |
Why?
|
| Male | 3 | 2019 | 20025 | 0.070 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2007 | 84 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 626 | 0.070 |
Why?
|
| Glucose | 1 | 2009 | 230 | 0.070 |
Why?
|
| Caspase 2 | 1 | 2006 | 7 | 0.070 |
Why?
|
| Brain Injuries | 1 | 2009 | 121 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2007 | 161 | 0.070 |
Why?
|
| Cysteine Endopeptidases | 1 | 2006 | 59 | 0.070 |
Why?
|
| Immunoprecipitation | 3 | 2011 | 131 | 0.070 |
Why?
|
| Receptor, Notch1 | 1 | 2006 | 17 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2009 | 339 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2006 | 100 | 0.070 |
Why?
|
| Cytokines | 1 | 2009 | 602 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2005 | 106 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2009 | 318 | 0.060 |
Why?
|
| Mitochondria | 1 | 2007 | 487 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2015 | 337 | 0.060 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2003 | 19 | 0.060 |
Why?
|
| Plant Preparations | 1 | 2003 | 27 | 0.060 |
Why?
|
| Chromosomes | 1 | 2003 | 37 | 0.060 |
Why?
|
| Tyrphostins | 1 | 2002 | 15 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2002 | 68 | 0.050 |
Why?
|
| Brain | 1 | 2009 | 1346 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2013 | 444 | 0.050 |
Why?
|
| Age Factors | 1 | 2003 | 1033 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 2016 | 92 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 58 | 0.030 |
Why?
|
| Risk Factors | 1 | 2003 | 3562 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2016 | 353 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 77 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2011 | 9 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2011 | 9 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2011 | 17 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2011 | 42 | 0.030 |
Why?
|
| Morpholines | 1 | 2011 | 69 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 113 | 0.020 |
Why?
|
| Thiazoles | 1 | 2011 | 74 | 0.020 |
Why?
|
| Chromones | 1 | 2011 | 54 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 75 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2011 | 118 | 0.020 |
Why?
|
| Soot | 1 | 2009 | 4 | 0.020 |
Why?
|
| Biomedical Engineering | 1 | 2009 | 5 | 0.020 |
Why?
|
| Radio Waves | 1 | 2008 | 4 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2009 | 40 | 0.020 |
Why?
|
| Glucose Oxidase | 1 | 2009 | 6 | 0.020 |
Why?
|
| Enzymes, Immobilized | 1 | 2009 | 14 | 0.020 |
Why?
|
| Computer Communication Networks | 1 | 2008 | 13 | 0.020 |
Why?
|
| Polystyrenes | 1 | 2009 | 19 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2010 | 103 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 53 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2008 | 38 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 146 | 0.020 |
Why?
|
| Adult | 2 | 2015 | 11712 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 448 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 708 | 0.020 |
Why?
|
| Tyrosine | 1 | 2007 | 118 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 972 | 0.020 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 8 | 0.020 |
Why?
|
| Water | 1 | 2009 | 296 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2006 | 15 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2005 | 92 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 173 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2005 | 141 | 0.020 |
Why?
|
| Cell Division | 1 | 2005 | 307 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 116 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2006 | 366 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2002 | 16 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 251 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 2002 | 33 | 0.010 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2002 | 44 | 0.010 |
Why?
|
| Postmenopause | 1 | 2002 | 128 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 10129 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 128 | 0.010 |
Why?
|
| Survivors | 1 | 2002 | 136 | 0.010 |
Why?
|
| Estrogens | 1 | 2002 | 202 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 1354 | 0.010 |
Why?
|